RENAL SYMPATHETIC DENERVATION FOR THE TREATMENT OF RESISTANT HYPERTENSION — SAFETY CONTROL BY ULTRASOUND TECHNIQUE
https://doi.org/10.18705/1607-419X-2013-19-2-139-147
Abstract
Objective. To assess the safety of transcatheter radiofrequency denervation (TRFD) of renal arteries (RA) in patients with resistant hypertension (RH) by ultrasound of the kidneys.
Design and methods. We assessed estimated glomerular filtration rate (eGFR) and performed ultrasound examination of the kidneys and RA at 1, 24 and 48 weeks after TRFD in 35 patients (mean age — 52 +- 10 years) with blood pressure (BP) > 160/100 mmHg despite 3 full-dose antihypertensive drugs as a part of the single-center prospective safety/efficacy study (NCT01499810).
Results. Office BP decreased by 34,9/18,2 mmHg (p < 0,001/0,001) and -42,7/-21,7 mmHg (p < 0,01/0,01) at 24 and 48 weeks after TRFD, respectively. No significant changes of eGFR and renal blood flow were found, however, the resistive index (RI) decreased significantly in segmental RA: from 0,62 Ѓ} 0,05 initially till 0,58 +-0,06 and 0,59 +- 0,06, respectively, at follow-up points (p = 0,003; p = 0,049 and p =0,063).
Conclusions. TRFD of RA has no adverse effect on either renal function or blood flow in the trunk and segmental branches of the RA. On the contrary, the decrease of resistive index in segmental RA after the intervention indicates improvement of renal blood flow.
About the Authors
T. M. RippRussian Federation
Corresponding author: Research Institute for Cardiology of SB RAMS, 111a Kievskaya st.,Tomsk,Russia, 638012. Phone: 8 (3822) 55–81–22. Fax: 8 (3822) 55–82–25. Е-mail: ripp@cardio.tsu.ru, rripp@mail.ru (Tatyana M.Ripp,MD, PhD, Senior Researcher at the Research Institute for Cardiology of SB RAMS).
V. F. Mordovin
Russian Federation
S. E. Pekarskiy
Russian Federation
T. R. Ryabova
Russian Federation
M. V. Zlobina
Russian Federation
A. L. Krilov
Russian Federation
V. A. Lechikaki
Russian Federation
S. V. Popov
Russian Federation
R. S. Karpov
Russian Federation
References
1. Тимофеева Т.Н., Деев А.Д., Шальнова С.А. и др. Аналитическая справка об эпидемиологической ситуации по АГ в 2008 году и ее динамике с 2003 по 2008 год по трем проведенным мониторингам // Министерство здравоохранения и социального развития Российской Федерации. — Москва, 2009. — С. 3. / Timofeeva T.N., Deev A.D., Shalnova S.A. et al. Analytic certifi cate on arterial hypertension epidemiology in 2008 and its changes from 2003 to 2008 according to three monitor studies // Ministry of Public Health and Social Development of Russian Federation. — Moscow, 2009. — P. 3 [Russian].
2. Stokes J., Kannel W., Wolf P. et al. Blood pressure as risk factor fjr cardiovascular disease. The Framingham Study — 30 years of follow-up // Hypertension. — 1989. — Vol. 13 (Suppl. 1). — Р. 13–18.
3. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции // Кардиоваск. тер. и профилакт. — 2005. — Т. 4, № 1. — С. 4–9. / Shalnova S.A., Deev A.D., Oganov R.G. Factors affecting cardiovascular mortality in Russian population // Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Profi laktika]. — 2005. — Vol. 4, № 1. — Р. 4–9 [Russian].
4. Lawes C.M., Vander Hoorn S., Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease 2001 // Lancet. — 2008. — Vol. 371, № 9623. — Р. 1513– 1518.
5. Kearney P.M., Whelton M., Reynolds K. еt al. Global burden of hypertension: analysis of worldwide data // Lancet. — 2005. — Vol. 365, № 9455. — Р. 217–223.
6. Erdine S., Ari O., Zanchetti A. et al. ESH-ESC guidelines for the management of hypertension // Herz. — 2006. — Vol. 31, № 4. — Р. 331–338.
7. Mancia G., Laurent S., Agabiti-Rosei E. еt al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // Hypertension. — 2009. — Vol. 27, № 11. — Р. 2121–2158.
8. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Hypertension. — 2007. — Vol. 25, № 6. — Р. 1105–1187.
9. Cuspidi C., Sala C., Negri F. et al. Prevalence of leftventricular hypertrophy in hypertension: an updated review of echocardiographic studies // Hum. Hypertens. — 2012. — Vol. 26, № 6. — Р. 343–349.
10. Howes F., Hansen E., Nelson M. Management of hypertension in general practice — a qualitative needs assessment of Australian // Gps. Aust. Fam. Physician. — 2012. — Vol. 41, № 5. — Р. 317–323.
11. Briganti E.M., Shaw J.E., Chadban S.J. et al. Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) // Med. J. Aust. — 2003. — Vol. 179, № 3. — Р. 135–139.
12. Cutler J.A., Sorlie P.D., Wolz M., Thom T., Fields L.E., Roccella E.J. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004 // Hypertension. — 2008. — Vol. 52, № 5. — Р. 818–827.
13. Falaschetti E., Chaudhury M., Mindell J., Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006 // Hypertension. — 2009. — Vol. 53, № 3. — Р. 480–486.
14. Howes F., Hansen E., Williams D. et al. Barriers to diagnosing and managing hypertension — a qualitative study in Australian general practicе // Aust. Fam. Physician. — 2010. — Vol. 39, № 6. — Р. 511–516.
15. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. — 2002. — Vol. 360, № 9349. — Р. 1903–1913.
16. Schlaich M.P., Sobotka P.A., Krum H. et al. Renal sympathetic-nerve ablation for uncontrolled hypertension // Engl. J. Med. — 2009. — Vol. 361, № 9. — Р. 932–934.
17. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months // Hypertension. — 2011. — Vol. 57, № 5. — Р. 911–917.
18. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial // Lancet. — 2010. — Vol. 376, № 9756. — Р. 1903–1909.
19. Lenartova M., Tak T. Iatrogenic pseudoaneurysm of femoral artery: case report and literature review // Clin. Med. Res. — 2003. — Vol. 1, № 3. — Р. 243–247.
20. Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology // J. Am. Soc. Echocardiography. — 2006. — Vol. 19, № 8. — Р. 955–971.
21. de Haan M.W., Kroon A.A., Flobbe K. et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound // J. Hum. Hypertens. — 2002. — Vol. 16, № 7. — Р. 501–507.
22. Radermacher J., Chavan A., Bleck J. et al. Use of doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis // N. Engl. J. Med. — 2001. — Vol. 344, № 6. — Р. 410– 417.
23. Mahfoud F., Cremers B., Janker J. et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension // Hypertension. — 2012. — Vol. 60, № 2. — Р. 419–424.
Review
For citations:
Ripp T.M., Mordovin V.F., Pekarskiy S.E., Ryabova T.R., Zlobina M.V., Krilov A.L., Lechikaki V.A., Popov S.V., Karpov R.S. RENAL SYMPATHETIC DENERVATION FOR THE TREATMENT OF RESISTANT HYPERTENSION — SAFETY CONTROL BY ULTRASOUND TECHNIQUE. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(2):139-147. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-2-139-147